Geojit Financial Services has reiterated an ACCUMULATE rating on Mankind Pharma Limited with a revised 12-month target price of Rs. 2,660, implying an upside potential of approximately 13% from the current market price of Rs. 2,362. The brokerage believes the company is emerging from a period of execution-related disruptions and is now positioned for a stronger growth trajectory driven by chronic therapies, improving acute segment performance, and expanding profitability. Robust domestic demand, healthy consumer healthcare momentum, and operational efficiencies supported a strong fourth-quarter performance. While the long-term outlook remains favorable, Geojit prefers to see sustained execution consistency and stronger prescription growth before turning more aggressive on the stock.

Geojit Maintains Accumulate Call as Recovery Gains Momentum

Mankind Pharma is showing clear signs of operational recovery. According to Geojit's latest assessment, the pharmaceutical major has successfully addressed several execution-related challenges that impacted performance earlier in FY26. Management commentary suggests business conditions have stabilized, enabling the company to regain growth momentum across key therapeutic segments.

The brokerage has rolled forward its valuation and now assigns a target price of Rs. 2,660 based on 37x FY28 estimated earnings. While management remains optimistic about future growth prospects, Geojit has adopted a measured approach, preferring to monitor consistency in domestic prescription growth and execution before upgrading its stance further.

Strong Fourth Quarter Driven by Domestic Business Expansion

Revenue growth accelerated despite a challenging operating backdrop. Consolidated revenue for Q4FY26 rose 11.8% year-over-year to Rs. 3,443 crore compared with Rs. 3,079 crore in the corresponding quarter last year.

The primary growth engine remained the domestic business, which delivered a healthy 13.4% increase in revenue to Rs. 2,886 crore. The performance was supported by sustained traction in chronic therapies and a sequential improvement in acute therapeutic categories such as gastrointestinal treatments and vitamins, minerals, and nutrition products.

Consumer healthcare continued to emerge as an important growth pillar. Revenue from this segment expanded 19.8% to Rs. 213 crore, benefiting from strong brand performance and improved e-commerce penetration. Meanwhile, international revenue increased a modest 4.2% to Rs. 557 crore as geopolitical uncertainties continued to weigh on overseas markets.

Margin Expansion Boosts Profitability

Operating leverage translated into substantial earnings growth.

Mankind Pharma reported EBITDA of Rs. 910 crore during Q4FY26, representing a sharp 32.7% year-over-year increase. More importantly, EBITDA margin expanded by 410 basis points to 26.4%, reflecting better cost management, favorable product mix, and stronger gross margins.

The margin-led earnings acceleration flowed directly to the bottom line. Reported profit after tax climbed 30.4% year-over-year to Rs. 559 crore, while adjusted profit increased 37.2% to Rs. 577 crore. Adjusted earnings per share improved to Rs. 14.0 from Rs. 10.2 in the same period last year.

Management Projects Stronger FY27 Performance

Guidance indicates confidence in the recovery trajectory.

Management expects FY27 revenue growth to exceed FY26 levels and has guided for double-digit top-line expansion. The company also expects EBITDA margins to remain within the 25.5%-26.5% range while pursuing market-share gains and aiming to outperform broader industry growth benchmarks.

A key strategic initiative includes the gradual scaling of its GLP-1 portfolio, targeted primarily at endocrinologists. The company is simultaneously building complementary opportunities in vitamins, minerals, protein supplements, and gastrointestinal therapies.

Management further indicated that over-the-counter growth will largely be driven by extensions of existing brands rather than aggressive new product launches, allowing the company to focus on scaling recently introduced offerings.

BSV Acquisition Continues to Deliver Strategic Benefits

The Bharat Serums and Vaccines business remains a meaningful growth contributor.

Several key BSV brands delivered exceptional growth during the quarter. Foligraf recorded a 52% increase in sales, while HMG grew 40%. The Anti-D franchise maintained its dominant market position with a 100% market share.

Notably, approximately 84% of BSV's domestic business falls under acute therapies, creating an additional growth lever as demand normalizes across the broader pharmaceutical landscape. The integration continues to strengthen Mankind Pharma's presence in specialized therapeutic categories.

Future Investments to Support Long-Term Expansion

Capital allocation remains focused on capacity building.

The company plans to invest approximately 6-7% of FY27 revenue toward capital expenditure. A significant portion of this spending will be directed toward the phased development of a new biotechnology facility in Vadodara.

This follows capital expenditure of roughly Rs. 700 crore during FY26 and demonstrates management's commitment to building future manufacturing and biologics capabilities that could support long-term growth and diversification.

Financial Outlook Suggests Improving Earnings Profile

The brokerage's revised projections indicate continued expansion across key financial metrics.

These projections imply earnings growth of 16.2% in FY27 followed by a stronger 25.0% expansion in FY28, supported by revenue growth, margin improvement, and lower leverage.

Key Levels for Investors

Current Market Price: Rs. 2,362

Target Price: Rs. 2,660

Expected Upside: 13%

Recommendation: ACCUMULATE

52-Week Range: Rs. 1,910 – Rs. 2,727

FY28 Estimated EPS: Rs. 71.9

FY28 Estimated P/E: 32.9x

Investment View

Mankind Pharma appears to be entering a more stable growth phase. The company's diversified therapeutic portfolio, strengthening chronic franchise, improving acute therapy performance, expanding consumer healthcare business, and disciplined cost structure provide a solid foundation for future earnings growth.

Although international markets remain somewhat constrained by geopolitical challenges and management execution will remain under scrutiny, the improving profitability profile and robust domestic momentum justify Geojit's positive stance. Investors seeking exposure to India's pharmaceutical sector may find the stock attractive on declines, particularly given the expected earnings acceleration over the next two fiscal years and the company's continued focus on operational efficiency and strategic capacity expansion.